Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04810611 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT04810611 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT04810611, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.
Interventions
- DRUG MBG453
- DRUG canakinumab
- DRUG NIS793
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04810611
The ClinicalTrials.gov registry entry for NCT04810611 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MBG453 is the first listed.
NCT04810611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04810611 about?
NCT04810611 is a clinical study titled "Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS". The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.
What is the current status of trial NCT04810611?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2021-06-18. Estimated completion is 2024-04-19.
What interventions are being tested in trial NCT04810611?
The interventions under investigation include: MBG453 (DRUG), canakinumab (DRUG), NIS793 (DRUG).
Who is sponsoring clinical trial NCT04810611?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.